

**LIFE SAVING DRUGS PROGRAM EXPERT PANEL
12th MEETING: 24 June 2022**

AGENDA

1. Standing business

- 1.1 Welcome, apologies and potential or actual Conflicts of Interest
- 1.2 Update on actions from previous meetings
- 1.3 Correspondence
- 1.4 Report from the Secretariat

2 Reviews of existing LSDP medicines

- 2.1 Elosulfase alfa (Vimizim[®]) – for the treatment of Mucopolysaccharidosis (MPS) Type IVA (Morquio A)

3 Applications for new LSDP medicines

- 3.1 Sebelipase alfa (Kanuma[®]) – for the treatment of infantile onset lysosomal acid lipase deficiency

4 Amendments to current listings

- 4.1 Migalastat (Galafold[®]) – for the treatment of Fabry disease

5 Other business